Skip to main content

Research Repository

Advanced Search

All Outputs (24)

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Preprint / Working Paper
Abhishek, A., Grainge, M. J., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., …Riley, R. D. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy (2023)
Journal Article
Astbury, S., Baskar, A., Grove, J. I., Kaye, P., Aravinthan, A. D., James, M., …Venkatachalapathy, S. V. (2023). Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy. Endoscopy International Open, 11(10), E983-E991. https://doi.org/10.1055/a-2163-8805

Background and study aims: Pancreatic cysts are common incidental findings, with an estimated prevalence of 13-15% in imaging done for other reasons. Diagnosis often relies on collection of cyst fluid, but tissue sampling using micro-forceps may allo... Read More about Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy.

Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol (2023)
Journal Article
Pavlides, M., Mózes, F. E., Akhtar, S., Wonders, K., Cobbold, J., Tunnicliffe, E. M., …Harrison, S. (2023). Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol. Contemporary Clinical Trials, 134, Article 107352. https://doi.org/10.1016/j.cct.2023.107352

Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small proportion of those with NAFLD will develop... Read More about Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.

Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study (2023)
Journal Article
Grove, J. I., Stephens, C., Lucena, M. I., Andrade, R. J., Weber, S., Gerbes, A., …on behalf of the TransBioLine consortium. (2023). Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study. Diagnostic and Prognostic Research, 7, Article 18. https://doi.org/10.1186/s41512-023-00155-z

A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consortium compri... Read More about Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study.

Application and Extension of the Alcohol Recovery Narratives Conceptual Framework (2023)
Journal Article
Subhani, M., Talat, U., Knight, H., Morling, J. R., Jones, K. A., Aithal, G. P., …Rennick-Egglestone, S. (2023). Application and Extension of the Alcohol Recovery Narratives Conceptual Framework. Qualitative Health Research, 33(13), 1203-1217. https://doi.org/10.1177/10497323231197384

Recovery narratives are personal stories of health problems and recovery. A systematic review proposed a conceptual framework characterising alcohol misuse recovery narratives, consisting of eight principal dimensions, each with types and subtypes. T... Read More about Application and Extension of the Alcohol Recovery Narratives Conceptual Framework.

Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL) (2023)
Journal Article
Lønsmann, I., Grove, J. I., Haider, A., Kaye, P., Karsdal, M. A., Leeming, D. J., & Aithal, G. P. (2023). Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL). Biology, 12(8), Article 1087. https://doi.org/10.3390/biology12081087

Background: Identification of progressive liver disease necessitates the finding of novel non-invasive methods to identify and monitor patients in need of early intervention. Investigating patients with early-liver injury may help identify unique bio... Read More about Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL).

Patients with Naproxen-Induced Liver Injury Display T-cell Memory Responses Towards an Oxidative (S)-O-Desmethyl Naproxen Metabolite but not the Acyl Glucuronide (2023)
Journal Article
Thomson, P., Fragkas, N., Kafu, L., Aithal, G., Lucena, M., Terracciano, L., …Naisbitt, D. (2024). Patients with Naproxen-Induced Liver Injury Display T-cell Memory Responses Towards an Oxidative (S)-O-Desmethyl Naproxen Metabolite but not the Acyl Glucuronide. Allergy, 79(1), 200-214. https://doi.org/10.1111/all.15830

Background: Exposure to non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI). Carboxylate bioactivation into reactive metabolites (e.g. acyl glucur... Read More about Patients with Naproxen-Induced Liver Injury Display T-cell Memory Responses Towards an Oxidative (S)-O-Desmethyl Naproxen Metabolite but not the Acyl Glucuronide.

Associations of objectively measured physical activity, sedentary time and cardiorespiratory fitness with adipose tissue insulin resistance and ectopic fat (2023)
Journal Article
Malaikah, S., Willis, S. A., Henson, J., Sargeant, J. A., Yates, T., Thackray, A. E., …King, J. A. (2023). Associations of objectively measured physical activity, sedentary time and cardiorespiratory fitness with adipose tissue insulin resistance and ectopic fat. International Journal of Obesity, 47(10), 1000–1007. https://doi.org/10.1038/s41366-023-01350-0

Background/objectives: Inadequate movement, excess adiposity, and insulin resistance augment cardiometabolic risk. This study examined the associations of objectively measured moderate-to-vigorous intensity physical activity (MVPA), sedentary time an... Read More about Associations of objectively measured physical activity, sedentary time and cardiorespiratory fitness with adipose tissue insulin resistance and ectopic fat.

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis (2023)
Journal Article
Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., …Hytiroglou, P. (2023). Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology, 8(8), 704-713. https://doi.org/10.1016/S2468-1253%2823%2900141-3

Background Histologically assessed liver fibrosis stage has prognostic significance in patients with non-alcoholic fatty liver disease (NAFLD) and is accepted as a surrogate endpoint in clinical trials for non-cirrhotic NAFLD. Our aim was to compare... Read More about Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.

Asia–Pacific association for study of liver guidelines on management of ascites in liver disease (2023)
Journal Article
Singh, V., De, A., Mehtani, R., Angeli, P., Maiwall, R., Satapathy, S., …Sarin, S. K. (2023). Asia–Pacific association for study of liver guidelines on management of ascites in liver disease. Hepatology International, 17(4), 792-826. https://doi.org/10.1007/s12072-023-10536-7

The development of ascites is a landmark event in the natural history of cirrhosis. This guidance statement by the Asia–Pacific Association for Study of Liver (APASL) provides an evidence-based approach to managing ascites and its complications in pa... Read More about Asia–Pacific association for study of liver guidelines on management of ascites in liver disease.

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023)
Journal Article
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., …Björnsson, E. S. (2023). Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. Journal of Hepatology, https://doi.org/10.1016/j.jhep.2023.04.033

Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held be... Read More about Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.

Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK Study (2023)
Journal Article
Papatheodoridi, M., Pallini, G., Aithal, G., Lim, H. K., Cobbold, J., Plaz Torres, M. C., …Tsochatzis, E. A. (2023). Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK Study. Clinical Gastroenterology and Hepatology, 21(12), 3107-3114.e3. https://doi.org/10.1016/j.cgh.2023.04.018

Background & Aims: It is unclear whether health-related quality of life (HRQoL) is impaired in patients with nonalcoholic fatty liver disease (NAFLD) without advanced fibrosis and how this compares with the general population. We aimed to assess HRQo... Read More about Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK Study.

Classifying the unclassifiable—a Delphi study to reach consensus on the fibrotic nature of diseases (2023)
Journal Article
Massen, G. M., Allen, R. J., Leavy, O. C., Selby, N. M., Aithal, G. P., Oliver, N., …Quint, J. K. (2023). Classifying the unclassifiable—a Delphi study to reach consensus on the fibrotic nature of diseases. QJM: An International Journal of Medicine, 116(6), 429-435. https://doi.org/10.1093/qjmed/hcad050

BACKGROUND: Traditionally, clinical research has focused on individual fibrotic diseases or fibrosis in a particular organ. However, it is possible for people to have multiple fibrotic diseases. While multi-organ fibrosis may suggest shared pathogeni... Read More about Classifying the unclassifiable—a Delphi study to reach consensus on the fibrotic nature of diseases.

Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study (2023)
Journal Article
Lee, J., Westphal, M., Vali, Y., Boursier, J., Ostroff, R., Alexander, L., …LITMUS investigators, L. I. (2023). Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study. Hepatology, 78(1), 258-271. https://doi.org/10.1097/HEP.0000000000000364

Background and Aims: Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning t... Read More about Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study (2023)
Journal Article
Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., …Bossuyt, P. M. (2023). Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. The Lancet Gastroenterology & Hepatology, 8(8), 714-725. https://doi.org/10.1016/S2468-1253%2823%2900017-1

Background: The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fibrosis—liver biopsy—is invasive and resource intensive. Non-invasive biomarkers are urgently needed, but few studies have compared these biomarkers in... Read More about Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (2023)
Journal Article
Pennisi, G., Enea, M., Falco, V., Aithal, G. P., Palaniyappan, N., Yilmaz, Y., …Petta, S. (2023). Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology, 78(1), 195-211. https://doi.org/10.1097/HEP.0000000000000351

Background and Aims: We evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in NAFLD patients with type 2 diabetes (T2D). Methods and Results: This was an individual patient data meta-analysis of 1780 patients with biopsy-proven NAF... Read More about Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.